-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604.O1.6 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Acute Myeloid Leukemia: An Understanding of Molecular Mechanisms Guides Rational Drug Combinations

Molecular Pharmacology and Drug Resistance in Myeloid Diseases Program: Oral and Poster Abstracts
Type: Oral
Monday, December 7, 2015: 2:45 PM-4:15 PM
W307, Level 3 (Orange County Convention Center)
Moderators:
Hetty E. Carraway, MD, MBA, Cleveland Clinic and Benjamin S Braun, MD, PhD, University of California, San Francisco

Disclosures:
No relevant conflicts of interest to declare.
2:45 PM

Rongqing Pan, MS1,2, Vivian Ruvolo, MS1*, Hong Mu, MD, PhD3*, Zhuanzhen Zheng, PhD1, Joel Leverson, PhD4*, Kensuke Kojima, PhD1, Marina Konopleva, MD, PhD1, Gwen Nichols, MD5 and Michael Andreeff, MD, PhD3

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
3Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
4AbbVie Inc., North Chicago, IL
5Roche Pharma Research & Early Development, Roche Innovation Center, New York, NY

3:00 PM

Anne-Louise Latif, MBChB1*, John J Cole1*, Joana Monteiro Campos2*, William Clark1*, Lynn McGarry, PhD1*, Claire Brock1*, Ashley Newcombe1*, Karen Keeshan, PhD2, Mhairi Copland, BSc (Hons) MB ChB PhD FRCP FRCPath2 and Peter D Adams, PhD1*

1Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom
2Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

3:15 PM

Sujan Piya1*, Teresa McQueen2*, Duncan Mak, BSc, MPhil2*, Marina Konopleva, MD, PhD3, Patrick Zweidler-McKay, MD, PhD4, Jing Lu, Ph.D.5*, Yimin Qian, Ph.D.5*, Michael Andreeff, MD, PhD6 and Gautam Borthakur, MD7

1Leukemia, UT MD Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Pediatrics Research, The University of Texas M D Anderson Cancer Center, Houston, TX
5Arvinas, LLC, New Haven, CT
6Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 PM

Anne-Kathrin Garz, M.Sc.1,2*, Stefan Habringer2,3*, Saskia Wolf1*, Binje Vick, PhD2,4*, Marie-Theresa Weickert, M.Sc.1*, Irmela Jeremias, MD2,5,6*, Karsten Spiekermann, MD2,7, Christian Peschel, MD2,8, Robert A.J. Oostendorp, PhD1*, Ulrich Keller2,3* and Katharina S. Götze, MD1,2

1III. Department of Medicine, Hematology and Medical Oncology, Technical University of Munich, Munich, Germany
2German Consortium for Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ), Munich, Germany
3III. Department of Internal Medicine, Hematology and Medical Oncology, Technische Universität München, Munich, Germany
4Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany
5Research Unit Gene Vectors, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany
6Department of Oncology, Dr. von Haunersches Kinderspital, Ludwig Maximilians University, Munich, Germany
7Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany
8III. Medizinische Klinik, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

3:45 PM

Catherine C. Smith, MD1, Aaron D. Viny, MD, MS2, Evan S. Massi, BS1*, Cyriac Kandoth, PhD2*, Nicholas D. Socci, PhD3*, Henry Hsu, MD4*, Brian West, PhD4*, Gideon Bollag, PhD4, Barry S. Taylor, PhD5*, Ross L. Levine, MD5 and Neil P. Shah1

1Department of Medicine, University of California at San Francisco, San Francisco, CA
2Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Bioinformatics, Memorial Sloan Kettering Cancer Center, New York, NY
4Plexxikon Inc., Berkeley, CA
5Memorial Sloan Kettering Cancer Center, New York, NY

4:00 PM

Quteba Ebrahem1*, Reda Z. Mahfouz, MD/PhD2, Lisa Durkin3*, Mikkael A. Sekeres, MD, MS4, Anjali S. Advani, MD5, Hetty E. Carraway, MD, MBA5, Sudipto Mukherjee, MD, PhD5, Betty K. Hamilton, MD6, Aaron T. Gerds, MD, MS5, Ronald Sobecks, MD7, Frederic J. Reu, MD8, Eric D. Hsi, MD9, Jaroslaw P. Maciejewski, MD, Ph.D.10 and Yogenthiran Saunthararajah, M.D.11

1Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussing Cancer Institute, Cleveland Clinic, Cleveland, OH
3Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute. Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Leukemia Program, Cleveland Clinic, Cleveland, OH
6Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Blood and Marrow Transplant, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
9Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
10Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

*signifies non-member of ASH